Norepinephrine–dopamine releasing agent
This is an old revision of this page, as edited by 85.194.1.120 (talk) at 20:40, 4 October 2018 (I changed wellbutrin to bupropion becuase wellbutrin is a brand name , I figured it would be better to use bupropion). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.
A norepinephrine–dopamine releasing agent (NDRA) is a type of drug which induces the release of norepinephrine (and epinephrine) and dopamine in the body and/or brain.
Examples of NDRAs include bupropion, phenethylamine, tyramine, amphetamine, methamphetamine, lisdexamfetamine, cathinone, methcathinone, propylhexedrine, phenmetrazine, pemoline, 4-methylaminorex, and benzylpiperazine.
A closely related type of drug is a norepinephrine–dopamine reuptake inhibitor (NDRI).
See also
References
| TAAR1 |
| ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|
| TAAR2 |
| ||||||||||
| TAAR5 |
| ||||||||||
‹See TfM›† References for all endogenous human TAAR1 ligands are provided at List of trace amines
‡ References for synthetic TAAR1 agonists can be found at TAAR1 or in the associated compound articles. For TAAR2 and TAAR5 agonists and inverse agonists, see TAAR for references.
| |||||||||||
 | This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |